Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea · Delayed Price · Currency is KRW 8,510.00
+10.00 (0.12%)
At close: Jan 30, 2026
KOSDAQ:318160 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 45,066 | 28,419 | 27,324 | 27,545 | 35,161 | 28,588 |
Other Revenue | -0 | -0 | - | - | - | - |
| 45,066 | 28,419 | 27,324 | 27,545 | 35,161 | 28,588 | |
Revenue Growth (YoY) | 62.01% | 4.00% | -0.80% | -21.66% | 22.99% | 18.61% |
Cost of Revenue | 27,825 | 19,374 | 19,596 | 19,902 | 24,935 | 18,694 |
Gross Profit | 17,241 | 9,045 | 7,729 | 7,643 | 10,225 | 9,895 |
Selling, General & Admin | 6,335 | 4,099 | 3,268 | 3,000 | 3,212 | 3,834 |
Research & Development | 655.7 | 486.14 | 656.59 | 742.09 | 718.36 | 467.12 |
Amortization of Goodwill & Intangibles | 48.75 | 53.37 | 48.98 | 41.04 | 25.87 | 16.15 |
Other Operating Expenses | - | - | - | - | - | 52.77 |
Operating Expenses | 7,842 | 5,008 | 4,579 | 4,108 | 4,616 | 4,603 |
Operating Income | 9,399 | 4,037 | 3,149 | 3,535 | 5,610 | 5,292 |
Interest Expense | -280.66 | -411.21 | -489.03 | -454.76 | -611.9 | -20.02 |
Interest & Investment Income | 323.94 | 519.2 | 340.99 | 103.29 | 114.53 | 257.04 |
Earnings From Equity Investments | - | - | - | - | 30.18 | - |
Currency Exchange Gain (Loss) | -78.18 | 971.21 | -257.14 | 754.46 | 1,227 | -697.11 |
Other Non Operating Income (Expenses) | -3.11 | 57.39 | -2,975 | -377.89 | 11.75 | -65.47 |
EBT Excluding Unusual Items | 9,361 | 5,173 | -231.01 | 3,560 | 6,381 | 4,766 |
Gain (Loss) on Sale of Investments | - | 5 | - | - | -1,500 | 22.23 |
Gain (Loss) on Sale of Assets | 120.39 | 12.55 | -218.15 | -19.17 | -93.86 | 0.04 |
Asset Writedown | - | - | -362.66 | - | -308.07 | - |
Pretax Income | 9,481 | 5,191 | -811.82 | 3,541 | 4,479 | 4,789 |
Income Tax Expense | 1,007 | 812.16 | 1,045 | 650.94 | 1,367 | 573.2 |
Earnings From Continuing Operations | 8,474 | 4,379 | -1,857 | 2,890 | 3,113 | 4,215 |
Minority Interest in Earnings | 4.36 | - | - | - | 18.85 | -28.14 |
Net Income | 8,478 | 4,379 | -1,857 | 2,890 | 3,131 | 4,187 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 411.33 |
Net Income to Common | 8,478 | 4,379 | -1,857 | 2,890 | 3,131 | 3,776 |
Net Income Growth | 500.07% | - | - | -7.71% | -25.21% | -7.05% |
Shares Outstanding (Basic) | 8 | 9 | 8 | 7 | 7 | 7 |
Shares Outstanding (Diluted) | 8 | 9 | 8 | 7 | 8 | 8 |
Shares Change (YoY) | -3.44% | 5.59% | 20.68% | -11.32% | -1.95% | -1.05% |
EPS (Basic) | 1016.85 | 490.80 | -219.80 | 412.78 | 447.27 | 527.47 |
EPS (Diluted) | 1016.85 | 490.80 | -220.00 | 412.78 | 396.66 | 520.03 |
EPS Growth | 522.33% | - | - | 4.06% | -23.72% | 4.21% |
Free Cash Flow | -3,665 | 7,247 | 1,131 | 77.49 | 3,889 | -9,507 |
Free Cash Flow Per Share | -439.57 | 812.26 | 133.91 | 11.07 | 492.62 | -1180.77 |
Gross Margin | 38.26% | 31.83% | 28.29% | 27.75% | 29.08% | 34.61% |
Operating Margin | 20.86% | 14.21% | 11.53% | 12.83% | 15.96% | 18.51% |
Profit Margin | 18.81% | 15.41% | -6.80% | 10.49% | 8.91% | 13.21% |
Free Cash Flow Margin | -8.13% | 25.50% | 4.14% | 0.28% | 11.06% | -33.26% |
EBITDA | 11,755 | 5,943 | 4,953 | 5,396 | 7,149 | 6,443 |
EBITDA Margin | 26.08% | 20.91% | 18.13% | 19.59% | 20.33% | 22.54% |
D&A For EBITDA | 2,356 | 1,906 | 1,803 | 1,861 | 1,539 | 1,151 |
EBIT | 9,399 | 4,037 | 3,149 | 3,535 | 5,610 | 5,292 |
EBIT Margin | 20.86% | 14.21% | 11.53% | 12.83% | 15.96% | 18.51% |
Effective Tax Rate | 10.63% | 15.65% | - | 18.38% | 30.51% | 11.97% |
Advertising Expenses | - | - | - | - | 0.8 | 131.23 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.